Abstract: An artificial eye assembly (100) comprising: —an anterior layer (50) comprising an anterior cavity (52); —a flow constricting (40) layer comprising a first aperture (42), and wherein the first aperture (42) is in fluid communication with the anterior cavity (52); —a shaping layer (30) comprising a second aperture and a shaping structure (32), wherein the shaping structure (32) is located within, partially within, or outside of the second aperture, and wherein the shaping structure comprises (32) one or more webs (33), the webs (33) connecting the structure (32) to the rest of the shaping layer (30), and wherein the second aperture is in fluid communication with the first aperture (42); —a flow resistive layer (20) comprising pores, and wherein pores of the layer are in fluid communication with the second aperture; —a posterior layer (10) comprising a posterior cavity (12), and wherein the posterior cavity (12) is in fluid communication with pores of the flow resistive layer (20); —a fluid inlet (13) located i

Abstract: An artificial eye assembly (100) comprising: ?an anterior layer (50) comprising an anterior cavity (52); ?a flow con-stricting (40) layer comprising a first aperture (42), and wherein the first aperture (42) is in fluid communication with the anterior cavity (52); ?a shaping layer (30) comprising a second aperture and a shaping structure (32), wherein the shaping structure (32) is located within, partially within, or outside of the second aperture, and wherein the shaping structure comprises (32) one or more webs (33), the webs (33) connecting the structure (32) to the rest of the shaping layer (30), and wherein the second aperture is in fluid communication with the first aperture (42); ?a flow resistive layer (20) comprising pores, and wherein pores of the layer are in fluid communication with the second aperture; ?a posterior layer (10) comprising a posterior cavity (12), and wherein the posterior cavity (12) is in fluid communication with pores of the flow resistive layer (20); ?a fluid inlet (13) located

Abstract: The present invention relates to a novel process of producing therapeutic GMP grade Müller cells and Miller cells obtainable therefrom, derived from stem cells using products that are free of animal-derived components. The Müller cells are suitable for treatment of eye disease, including glaucoma. There is also provided a cell culture medium.

Abstract: A drainage device for use in an eye to drain aqueous humour so as to reduce intraocular pressure or for treating glaucoma. The device has a multi-lumen tube having a first end, a second end opposite the first end, and a plurality of lumen extending between the first end and the second end. At least one of the lumen is sealed at the first end. A flow through the multi-lumen tube is adjusted by forming at least one aperture open in one of the lumen through a wall of the tube and/or sealing at least one aperture open in one of the lumen. The tube has a longitudinal axis through the first end and the second end, and an outer surface extending between the first end and the second end. A cross-section perpendicular to the longitudinal axis has a non-circular shape at the outer surface with an aspect ratio of at least 3:1.

Abstract: A method for the production of retinal cells, useful in transplantation therapy, comprises: (i) obtaining one or more mammalian adult Müller cells; and (ii) culturing the cells in the presence of an extracellular matrix protein and a growth factor to thereby induce dedifferentiation of the Müller cells into a progenitor phenotype.

Abstract: A method for the production of retinal cells, useful in transplantation therapy, comprises: (i) obtaining one or more mammalian adult Müller cells; and (ii) culturing the cells in the presence of an extracellular matrix protein and a growth factor to thereby induce dedifferentiation of the Müller cells into a progenitor phenotype.

Abstract: A method for the production of retinal cells, useful in transplantation therapy, comprises: (i) obtaining one or more mammalian adult Müller cells; and (ii) culturing the cells in the presence of an extracellular matrix protein and a growth factor to thereby induce dedifferentiation of the Müller cells into a progenitor phenotype.

Abstract: A gonioscopy lens employs a plurality of mirror sets so that substantially the entire periphery of the anterior chamber of an eye can be viewed without rotating or moving the contact lens. Each mirror set comprises a first mirror position anterior to the eye on one side of the optical axis and a second mirror positioned posterior to the first mirror on the opposite side of the optical axis. Each set is oriented relative to each other so that the second mirror receives light rays from the peripheral portion of the anterior chamber, reflects those rays to the second mirror to the first mirror, and then reflects the light rays in a generally anterior direction so that they can be used by an ophthalmologist employing the lens. The image viewed by the ophthalmologist is upright and located over its actual position.

Abstract: A gonioscopy lens employs a plurality of mirror sets so that substantially the entire periphery of the anterior chamber of an eye can be viewed without rotating or moving the contact lens. Each mirror set comprises a first mirror position anterior to the eye on one side of the optical axis and a second mirror positioned posterior to the first mirror on the opposite side of the optical axis. Each set is oriented relative to each other so that the second mirror receives light rays from the peripheral portion of the anterior chamber, reflects those rays to the second mirror to the first mirror, and then reflects the light rays in a generally anterior direction so that they can be used by an ophthalmologist employing the lens. The image viewed by the ophthalmologist is upright and located over its actual position.

Abstract: The use of an MMP inhibitor, especially a collagenase inhibitor, in the manufacture of a medicament for the treatment of a natural or artificial tissue comprising extracellular matrix components to inhibit contraction of the tissue and methods for the treatment of tissue comprising extracellular matrix components to inhibit contraction.

Abstract: The use of an MMP inhibitor, especially a collagenase inhibitor, in the manufacture of a medicament for the treatment of a natural or artificial tissue comprising extracellular matrix components to inhibit contraction of the tissue and methods for the treatment of tissue comprising extracellular matrix components to inhibit contraction.

Abstract: The use of an MMP inhibitor, especially a collagenase inhibitor, in the manufacture of a medicament for the treatment of a natural or artificial tissue comprising extracellular matrix components to inhibit contraction of the tissue and methods for the treatment of tissue comprising extracellular matrix components to inhibit contraction.

Abstract: The use of an MMP inhibitor, especially a collagenase inhibitor, in the manufacture of a medicament for the treatment of a natural or artificial tissue comprising extracellular matrix components to inhibit contraction of the tissue and methods for the treatment of tissue comprising extracellular matrix components to inhibit contraction.